Research ExplorerPublications68Ga-PSMA-11 Positron Emission Tomography/Computed Tomograph...

68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy

Standard

68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy. / Esen, Tarik; Falay, Okan; Tarim, Kayhan; Armutlu, Ayse; Koseoglu, Ersin; Kilic, Mert; Seymen, Hülya; Sarikaya, Ahmet Furkan; Kiremit, Murat Can; Balbay, Mevlana Derya; Canda, Abdullah Erdem; Baydar, Dilek Ertoy; Kordan, Yakup; Demirkol, Mehmet Onur; Tilki, Derya.

In: EUR UROL FOCUS, Vol. 7, No. 2, 03.2021, p. 288-293.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Esen, T, Falay, O, Tarim, K, Armutlu, A, Koseoglu, E, Kilic, M, Seymen, H, Sarikaya, AF, Kiremit, MC, Balbay, MD, Canda, AE, Baydar, DE, Kordan, Y, Demirkol, MO & Tilki, D 2021, '68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy', EUR UROL FOCUS, vol. 7, no. 2, pp. 288-293. https://doi.org/10.1016/j.euf.2021.01.004

APA

Esen, T., Falay, O., Tarim, K., Armutlu, A., Koseoglu, E., Kilic, M., Seymen, H., Sarikaya, A. F., Kiremit, M. C., Balbay, M. D., Canda, A. E., Baydar, D. E., Kordan, Y., Demirkol, M. O., & Tilki, D. (2021). 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy. EUR UROL FOCUS, 7(2), 288-293. https://doi.org/10.1016/j.euf.2021.01.004

Vancouver

Esen T, Falay O, Tarim K, Armutlu A, Koseoglu E, Kilic M et al. 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy. EUR UROL FOCUS. 2021 Mar;7(2):288-293. https://doi.org/10.1016/j.euf.2021.01.004

Bibtex

@article{b7cea50e69484372a8a546aa884439b7,
title = "68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy",
abstract = "BACKGROUND: Results from prospective trials have shown higher accuracy of prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) in detection of lymph node metastasis (LNM) compared to conventional imaging.OBJECTIVE: To evaluate the accuracy of 68Ga-PSMA-11 PET/CT for LNM detection in patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (PLND).DESIGN, SETTING, AND PARTICIPANTS: Between June 2014 and November 2020, 96 patients with 68Ga-PSMA PET/CT for primary staging underwent RP and extended PLND.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The results from 68Ga-PSMA PET/CT were compared with histologic data from primary PLND in 96 patients. All 68Ga-PSMA PET/CT scans were centrally reviewed.RESULTS AND LIMITATIONS: Of 96 patients, 15.6% (n = 15) harbored LNMs. The median prostate-specific antigen at 68Ga-PSMA PET/CT was 8.0 ng/ml (interquartile range 5.5-11.7). The majority of patients had intermediate- (52.1%) or high-risk disease (41.7%). Biopsy grade group 4 and 5 was present in 22.9% and 15.6%, respectively. The 68Ga-PSMA PET/CT scans identified eight of 15 patients (53.3%) as LN-positive (true positive). The calculated per-patient sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 68Ga-PSMA PET/CT in the detection of LNM were 53.3%, 98.8%, 88.9%, 92.0%, and 91.7%, respectively. The per-patient sensitivity and specificity in the detection of LNMs larger than 2 mm were 61.5% and 98.8%, respectively. The main limitation is the retrospective design of the study.CONCLUSIONS: 68Ga-PSMA PET/CT is accurate in lymph node staging and the results support its use for primary staging of prostate cancer.PATIENT SUMMARY: We compared prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) findings with histopathology results after extended lymph node dissection and showed that it is accurate in detecting lymph node metastases. Our results support the use of PSMA PET/CT for primary staging of prostate cancer.",
author = "Tarik Esen and Okan Falay and Kayhan Tarim and Ayse Armutlu and Ersin Koseoglu and Mert Kilic and H{\"u}lya Seymen and Sarikaya, {Ahmet Furkan} and Kiremit, {Murat Can} and Balbay, {Mevlana Derya} and Canda, {Abdullah Erdem} and Baydar, {Dilek Ertoy} and Yakup Kordan and Demirkol, {Mehmet Onur} and Derya Tilki",
note = "Copyright {\textcopyright} 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2021",
month = mar,
doi = "10.1016/j.euf.2021.01.004",
language = "English",
volume = "7",
pages = "288--293",
journal = "EUR UROL FOCUS",
issn = "2405-4569",
publisher = "Elsevier BV",
number = "2",

}

RIS

TY - JOUR

T1 - 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy

AU - Esen, Tarik

AU - Falay, Okan

AU - Tarim, Kayhan

AU - Armutlu, Ayse

AU - Koseoglu, Ersin

AU - Kilic, Mert

AU - Seymen, Hülya

AU - Sarikaya, Ahmet Furkan

AU - Kiremit, Murat Can

AU - Balbay, Mevlana Derya

AU - Canda, Abdullah Erdem

AU - Baydar, Dilek Ertoy

AU - Kordan, Yakup

AU - Demirkol, Mehmet Onur

AU - Tilki, Derya

N1 - Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2021/3

Y1 - 2021/3

N2 - BACKGROUND: Results from prospective trials have shown higher accuracy of prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) in detection of lymph node metastasis (LNM) compared to conventional imaging.OBJECTIVE: To evaluate the accuracy of 68Ga-PSMA-11 PET/CT for LNM detection in patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (PLND).DESIGN, SETTING, AND PARTICIPANTS: Between June 2014 and November 2020, 96 patients with 68Ga-PSMA PET/CT for primary staging underwent RP and extended PLND.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The results from 68Ga-PSMA PET/CT were compared with histologic data from primary PLND in 96 patients. All 68Ga-PSMA PET/CT scans were centrally reviewed.RESULTS AND LIMITATIONS: Of 96 patients, 15.6% (n = 15) harbored LNMs. The median prostate-specific antigen at 68Ga-PSMA PET/CT was 8.0 ng/ml (interquartile range 5.5-11.7). The majority of patients had intermediate- (52.1%) or high-risk disease (41.7%). Biopsy grade group 4 and 5 was present in 22.9% and 15.6%, respectively. The 68Ga-PSMA PET/CT scans identified eight of 15 patients (53.3%) as LN-positive (true positive). The calculated per-patient sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 68Ga-PSMA PET/CT in the detection of LNM were 53.3%, 98.8%, 88.9%, 92.0%, and 91.7%, respectively. The per-patient sensitivity and specificity in the detection of LNMs larger than 2 mm were 61.5% and 98.8%, respectively. The main limitation is the retrospective design of the study.CONCLUSIONS: 68Ga-PSMA PET/CT is accurate in lymph node staging and the results support its use for primary staging of prostate cancer.PATIENT SUMMARY: We compared prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) findings with histopathology results after extended lymph node dissection and showed that it is accurate in detecting lymph node metastases. Our results support the use of PSMA PET/CT for primary staging of prostate cancer.

AB - BACKGROUND: Results from prospective trials have shown higher accuracy of prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) in detection of lymph node metastasis (LNM) compared to conventional imaging.OBJECTIVE: To evaluate the accuracy of 68Ga-PSMA-11 PET/CT for LNM detection in patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (PLND).DESIGN, SETTING, AND PARTICIPANTS: Between June 2014 and November 2020, 96 patients with 68Ga-PSMA PET/CT for primary staging underwent RP and extended PLND.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The results from 68Ga-PSMA PET/CT were compared with histologic data from primary PLND in 96 patients. All 68Ga-PSMA PET/CT scans were centrally reviewed.RESULTS AND LIMITATIONS: Of 96 patients, 15.6% (n = 15) harbored LNMs. The median prostate-specific antigen at 68Ga-PSMA PET/CT was 8.0 ng/ml (interquartile range 5.5-11.7). The majority of patients had intermediate- (52.1%) or high-risk disease (41.7%). Biopsy grade group 4 and 5 was present in 22.9% and 15.6%, respectively. The 68Ga-PSMA PET/CT scans identified eight of 15 patients (53.3%) as LN-positive (true positive). The calculated per-patient sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 68Ga-PSMA PET/CT in the detection of LNM were 53.3%, 98.8%, 88.9%, 92.0%, and 91.7%, respectively. The per-patient sensitivity and specificity in the detection of LNMs larger than 2 mm were 61.5% and 98.8%, respectively. The main limitation is the retrospective design of the study.CONCLUSIONS: 68Ga-PSMA PET/CT is accurate in lymph node staging and the results support its use for primary staging of prostate cancer.PATIENT SUMMARY: We compared prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) findings with histopathology results after extended lymph node dissection and showed that it is accurate in detecting lymph node metastases. Our results support the use of PSMA PET/CT for primary staging of prostate cancer.

U2 - 10.1016/j.euf.2021.01.004

DO - 10.1016/j.euf.2021.01.004

M3 - SCORING: Journal article

C2 - 33509671

VL - 7

SP - 288

EP - 293

JO - EUR UROL FOCUS

JF - EUR UROL FOCUS

SN - 2405-4569

IS - 2

ER -